LAVAL, QUEBEC and BERLIN, GERMANY -- (Marketwire) -- 05/03/10 -- Warnex Medical Laboratories, a division of Warnex Inc. (TSX: WNX), and Epigenomics AG (Frankfurt Prime Standard: ECX), a cancer molecular diagnosis company based in Berlin, Germany, today announced that they have entered into a non-exclusive licensing agreement for Epigenomics' colorectal cancer biomarker Septin9. Under the terms of the agreement, Warnex has obtained the rights to establish a laboratory-developed test for Septin9 and offer colorectal cancer blood testing services in Canada. Warnex plans to launch the testing service in the next few months. As the first laboratory to offer Septin9
More...
More...